

10 years of denosumab treatment in postmenopausal women
from the phase 3 randomised FREEDOM trial and open-

Lancet Diabetes and Endocrinology, the
5, 513-523

DOI: [10.1016/s2213-8587\(17\)30138-9](https://doi.org/10.1016/s2213-8587(17)30138-9)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Safety of long-term denosumab therapy for osteoporosis. <i>Lancet Diabetes and Endocrinology</i> ,the, 2017, 5, 485-487.	11.4	11
2	Antiresorptives: Safety Concernsâ€”Clinical Perspective. <i>Toxicologic Pathology</i> , 2017, 45, 859-863.	1.8	12
3	Interventions for managing medication-related osteonecrosis of the jaw. <i>The Cochrane Library</i> , 2017, 2017, CD012432.	2.8	82
4	Denosumab treatment in postmenopausal women with osteoporosis. <i>Lancet Diabetes and Endocrinology</i> ,the, 2017, 5, 767-768.	11.4	2
5	Investigational anabolic agents for the treatment of osteoporosis: an update on recent developments. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1137-1144.	4.1	13
6	Denosumab treatment in postmenopausal women with osteoporosis. <i>Lancet Diabetes and Endocrinology</i> ,the, 2017, 5, 767.	11.4	1
7	Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. <i>Bone</i> , 2017, 105, 11-17.	2.9	373
8	How Basic Science Discoveries Have Shaped the Treatment of Bone and Mineral Disorders. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 2324-2330.	2.8	1
9	Effects of 3-year denosumab treatment on hip structure in Japanese postmenopausal women and men with osteoporosis. <i>Bone Reports</i> , 2017, 7, 164-171.	0.4	6
10	Use of bone turnover markers in postmenopausal osteoporosis. <i>Lancet Diabetes and Endocrinology</i> ,the, 2017, 5, 908-923.	11.4	336
11	Osteoporosis treatment: recent developments and ongoing challenges. <i>Lancet Diabetes and Endocrinology</i> ,the, 2017, 5, 898-907.	11.4	615
12	Key Triggers of Osteoclast-Related Diseases and Available Strategies for Targeted Therapies: A Review. <i>Frontiers in Medicine</i> , 2017, 4, 234.	2.6	108
13	Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?. <i>Calcified Tissue International</i> , 2018, 103, 107-108.	3.1	7
14	Warning of an increased risk of vertebral fracture after stopping denosumab. <i>Cmaj</i> , 2018, 190, E485-E486.	2.0	16
15	FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1219-1226.	2.8	108
16	Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. <i>Lancet Diabetes and Endocrinology</i> ,the, 2018, 6, 445-454.	11.4	148
17	Long-term treatment strategies for postmenopausal osteoporosis. <i>Current Opinion in Rheumatology</i> , 2018, 30, 420-426.	4.3	19
18	Update on osteoporosis treatment. <i>Medicina ClÃnica (English Edition)</i> , 2018, 150, 479-486.	0.2	8

#	ARTICLE	IF	CITATIONS
19	Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis. <i>Calcified Tissue International</i> , 2018, 103, 50-54.	3.1	61
20	Underestimation of Vertebral Fractures After Denosumab Discontinuation. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 547-547.	2.8	17
21	Vertebral Fractures Following Denosumab Discontinuation in Patients with Prolonged Exposure to Bisphosphonates. <i>Calcified Tissue International</i> , 2018, 103, 44-49.	3.1	40
22	Denosumab: A Review in Postmenopausal Osteoporosis. <i>Drugs and Aging</i> , 2018, 35, 163-173.	2.7	114
23	Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 413-428.	2.4	17
24	Romozosumab to rebuild the foundations of bone strength. <i>Nature Reviews Rheumatology</i> , 2018, 14, 128-128.	8.0	14
25	Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates. <i>Archives of Osteoporosis</i> , 2018, 13, 1.	2.4	15
26	Effects and management of denosumab discontinuation. <i>Joint Bone Spine</i> , 2018, 85, 515-517.	1.6	16
27	Tratamiento de la osteoporosis. <i>Medicina Clínica</i> , 2018, 150, 479-486.	0.6	27
28	Addressing the crisis in the treatment of osteoporosis. <i>Nature Reviews Rheumatology</i> , 2018, 14, 67-68.	8.0	34
31	Treatment of osteoporosis: whom, how and for how long?. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2018, 79, 259-264.	0.5	6
32	Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system. <i>Current Opinion in Pharmacology</i> , 2018, 40, 110-119.	3.5	63
33	Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis. <i>Odontology / the Society of the Nippon Dental University</i> , 2018, 106, 469-480.	1.9	21
34	Postmenopausal Osteoporosis Treatment Update. <i>Current Treatment Options in Rheumatology</i> , 2018, 4, 142-157.	1.4	2
35	THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. <i>European Journal of Endocrinology</i> , 2018, 179, R31-R45.	3.7	94
36	A new vaccine targeting RANKL, prepared by incorporation of an unnatural Amino acid into RANKL, prevents OVX-induced bone loss in mice. <i>Biochemical and Biophysical Research Communications</i> , 2018, 499, 648-654.	2.1	10
37	Changes of Circulating MicroRNAs in Response to Treatment With Teriparatide or Denosumab in Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1206-1213.	3.6	48
38	Postmenopausal Osteoporosis: A Clinical Review. <i>Journal of Women's Health</i> , 2018, 27, 1093-1096.	3.3	61

#	ARTICLE	IF	CITATIONS
39	Osteogenesis imperfecta and therapeutics. <i>Matrix Biology</i> , 2018, 71-72, 294-312.	3.6	75
40	Bone: best papers of the year 2017. <i>Archives of Osteoporosis</i> , 2018, 13, 29.	2.4	0
41	Rapid onset of osteonecrosis of the jaw in patients switching from bisphosphonates to denosumab. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2018, 125, 27-30.	0.4	28
42	Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study. <i>Osteoporosis International</i> , 2018, 29, 41-47.	3.1	77
43	Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 298-306.	2.8	63
44	RANKL and RANK: From Mammalian Physiology to Cancer Treatment. <i>Trends in Cell Biology</i> , 2018, 28, 213-223.	7.9	72
45	An Essential Warning. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 188-189.	2.8	17
46	The anti-tumor effect of RANKL inhibition in malignant solid tumors – A systematic review. <i>Cancer Treatment Reviews</i> , 2018, 62, 18-28.	7.7	103
47	Prevention of fractures in patients with osteoporosis. <i>Lancet, The</i> , 2018, 391, 184-186.	13.7	10
48	Monoclonal antibodies for treating osteoporosis. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 149-157.	3.1	45
49	Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 15-22.	2.0	11
50	Second Colombian Consensus on the Management of Post-menopausal Osteoporosis: 2017 update. <i>Revista Colombiana De Reumatolog�a (English Edition)</i> , 2018, 25, 184-210.	0.0	0
51	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Quality of DXA Scans and Reports. <i>Endocrine Practice</i> , 2018, 24, 220-229.	2.1	14
53	The enigma of atypical femoral fractures. <i>EFORT Open Reviews</i> , 2018, 3, 494-500.	4.1	32
54	Postmenopausal osteoporosis: Assessment and management. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2018, 32, 739-757.	4.7	64
56	Functional Calcium Binding Peptides from Pacific Cod (<i>Gadus macrocephalus</i>) Bone: Calcium Bioavailability Enhancing Activity and Anti-Osteoporosis Effects in the Ovariectomy-Induced Osteoporosis Rat Model. <i>Nutrients</i> , 2018, 10, 1325.	4.1	44
57	Drug holidays in women treated for postmenopausal osteoporosis. <i>Menopause</i> , 2018, 25, 1152-1154.	2.0	2
58	Glucocorticoid-induced osteoporosis in systemic lupus erythematosus. <i>Rheumatology Practice and Research</i> , 2018, 3, 205990211880251.	0.0	0

#	ARTICLE	IF	CITATIONS
59	New and emerging concepts in the use of denosumab for the treatment of osteoporosis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2018, 10, 209-223.	2.7	56
60	Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 453-459.	2.0	23
61	Roles of the RANKL-RANK axis in antitumour immunity – implications for therapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 676-693.	27.6	77
62	Real-world Management of Women with Postmenopausal Osteoporosis Treated with Denosumab: A Prospective Observational Study in the Czech Republic and Slovakia. <i>Advances in Therapy</i> , 2018, 35, 1713-1728.	2.9	5
63	Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway. <i>Nature Reviews Endocrinology</i> , 2018, 14, 605-623.	9.6	42
64	Efficacy of teriparatide and denosumab combination treatment in a patient with atypical femoral fracture and Behçet's disease: a case report and review of the literature. <i>Modern Rheumatology Case Reports</i> , 2018, 2, 92-96.	0.7	2
65	Update on osteoporosis in men. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2018, 32, 759-772.	4.7	49
66	Metabolomics-based profiles predictive of low bone mass in menopausal women. <i>Bone Reports</i> , 2018, 9, 11-18.	0.4	33
67	Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures. <i>Current Osteoporosis Reports</i> , 2018, 16, 519-529.	3.6	92
68	Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2498-2509.	3.6	66
69	Denosumab in the treatment of glucocorticoid-induced osteoporosis. <i>Rheumatology International</i> , 2018, 38, 1975-1984.	3.0	20
70	Letter to the Editor: “Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis” • <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2756-2757.	3.6	1
72	The underlying pathophysiology and therapeutic approaches for osteoporosis. <i>Medicinal Research Reviews</i> , 2018, 38, 2024-2057.	10.5	67
73	Pre-treatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 637-642.	2.0	2
74	Advances and Unmet Needs in the Therapeutics of Bone Fragility. <i>Frontiers in Endocrinology</i> , 2018, 9, 505.	3.5	20
75	Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study. <i>Archives of Osteoporosis</i> , 2018, 13, 85.	2.4	22
76	Review of the guideline of the American College of Physicians on the treatment of osteoporosis. <i>Osteoporosis International</i> , 2018, 29, 1505-1510.	3.1	26
77	Certainties and Uncertainties About Denosumab Discontinuation. <i>Calcified Tissue International</i> , 2018, 103, 1-4.	3.1	22

#	ARTICLE	IF	CITATIONS
78	Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results. <i>Breast Cancer</i> , 2019, 26, 106-112.	2.9	8
81	Effect of Denosumab on Femoral Periprosthetic BMD and Early Femoral Stem Subsidence in Postmenopausal Women Undergoing Cementless Total Hip Arthroplasty. <i>JBMR Plus</i> , 2019, 3, e10217.	2.7	27
82	Bench-to-bedside strategies for osteoporotic fracture: From osteoimmunology to mechanosensation. <i>Bone Research</i> , 2019, 7, 25.	11.4	47
83	Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 2220-2228.	2.8	103
84	Management of Osteoporosis in Postmenopausal Women. , 2019, , 367-385.		0
86	Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3450-3461.	3.6	17
87	Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. <i>Osteoporosis International</i> , 2019, 30, 2437-2448.	3.1	72
88	Denosumab Treatment Improves Health-Related Quality of Life in Osteoporosis: Is It Still an Attractive Topic?. <i>JBMR Plus</i> , 2019, 3, e10220.	2.7	1
89	Practical management of fracture risk among peri- and postmenopausal women. <i>Fertility and Sterility</i> , 2019, 112, 782-790.	1.0	2
90	The influence of genetics in musculoskeletal diseases: A personal review of progress over 40 years. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1797-1802.	1.9	0
92	Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. <i>Advances in Therapy</i> , 2019, 36, 2811-2824.	2.9	60
95	Lessons learned with Bone Health TeleECHO: making treatment decisions when guidelines conflict. <i>Osteoporosis International</i> , 2019, 30, 2401-2406.	3.1	7
96	<p>Analysis of three-dimensional bone mineral density and bone strength measured by quantitative computed tomography following denosumab discontinuation in a patient with postmenopausal osteoporosis</p>. <i>Clinical Interventions in Aging</i> , 2019, Volume 14, 1445-1450.	2.9	2
97	Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 2916-2946.	1.6	127
98	Glucocorticoid-induced osteoporosis: from clinical trials to clinical practice. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2019, 11, 1759720X1987646.	2.7	18
99	Osteoporosis. <i>Lancet, The</i> , 2019, 393, 364-376.	13.7	1,252
100	MicroRNA and Human Bone Health. <i>JBMR Plus</i> , 2019, 3, 2-13.	2.7	38
101	Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis. <i>Osteoporosis International</i> , 2019, 30, 995-1002.	3.1	3

#	ARTICLE	IF	CITATIONS
102	Treating osteoporosis to prevent fractures: current concepts and future developments. <i>Journal of Internal Medicine</i> , 2019, 285, 381-394.	6.0	113
103	Reply. <i>Arthritis and Rheumatology</i> , 2019, 71, 1771-1772.	5.6	0
104	Bisphosphonates as a First-Line Treatment for Glucocorticoid-Induced Osteoporosis: Comment on the Article by Saag et al. <i>Arthritis and Rheumatology</i> , 2019, 71, 1770-1771.	5.6	1
106	Fracture risk following intermission of osteoporosis therapy. <i>Osteoporosis International</i> , 2019, 30, 1733-1743.	3.1	38
107	Fracture prediction, imaging and screening in osteoporosis. <i>Nature Reviews Endocrinology</i> , 2019, 15, 535-547.	9.6	122
108	Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group. <i>Osteoporosis International</i> , 2019, 30, 1855-1864.	3.1	20
109	Recommendations by the Spanish Society of Rheumatology on Osteoporosis. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 188-210.	0.3	5
110	Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2443-2452.	3.6	48
111	Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study. <i>Osteoporosis International</i> , 2019, 30, 1455-1464.	3.1	16
112	Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women. <i>Bone</i> , 2019, 123, 191-195.	2.9	26
113	Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1595-1622.	3.6	470
114	Impacts of Psychological Stress on Osteoporosis: Clinical Implications and Treatment Interactions. <i>Frontiers in Psychiatry</i> , 2019, 10, 200.	2.6	60
115	Relationship Between Bone Mineral Density <i>T</i> -Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1033-1040.	2.8	79
116	Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1123-1134.	1.8	26
117	Adverse Hair Reactions to New Targeted Therapies for Cancer. <i>Actas Dermo-sifiligráficas</i> , 2019, 110, 182-192.	0.4	0
118	Reacciones capilares de las nuevas terapias diana dirigidas contra el cáncer. <i>Actas Dermo-sifiligráficas</i> , 2019, 110, 182-192.	0.4	11
119	Antiresorptive and anabolic agents in the prevention and reversal of bone fragility. <i>Nature Reviews Rheumatology</i> , 2019, 15, 225-236.	8.0	73
120	Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial. <i>Arthritis and Rheumatology</i> , 2019, 71, 1174-1184.	5.6	102

#	ARTICLE	IF	CITATIONS
121	Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management. <i>Endocrine Reviews</i> , 2019, 40, 333-368.	20.1	136
122	Myeloma bone disease: from biology findings to treatment approaches. <i>Blood</i> , 2019, 133, 1534-1539.	1.4	88
123	Spontaneous vertebral fractures after denosumab discontinuation: A case collection and review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 197-203.	3.4	21
124	National Institutes of Health Pathways to Prevention Workshop: Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention. <i>Annals of Internal Medicine</i> , 2019, 171, 51-57.	3.9	22
125	Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naïve and castration-sensitive prostate cancer. <i>Canadian Urological Association Journal</i> , 2019, 14, 17-23.	0.6	17
126	Spontaneous Vertebral Fractures in Males with Osteoporosis After Denosumab Discontinuation. <i>Journal of Clinical Rheumatology</i> , 2021, 27, S581-S584.	0.9	13
128	Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China). <i>Menopause</i> , 2019, 26, 929-939.	2.0	14
129	Therapeutic effect of percutaneous kyphoplasty combined with anti-osteoporosis drug on postmenopausal women with osteoporotic vertebral compression fracture and analysis of postoperative bone cement leakage risk factors: a retrospective cohort study. <i>Journal of Orthopaedic Surgery and Research</i> , 2019, 14, 452.	2.3	20
130	Detection and management of atypical femur fractures. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2019, 26, 283-290.	2.3	5
131	Gorham-Stout Syndrome of the Shoulder Girdle Successfully Controlled by Antiresorptive Agents. <i>JBJS Case Connector</i> , 2019, 9, e0285-e0285.	0.3	5
132	Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency. <i>Osteoporosis International</i> , 2019, 30, 241-249.	3.1	15
133	Side effects of drugs for osteoporosis and metastatic bone disease. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1063-1071.	2.4	78
134	Reduction of Cortical Bone Turnover and Erosion Depth After 2 and 3 Years of Denosumab: Iliac Bone Histomorphometry in the FREEDOM Trial. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 626-631.	2.8	12
135	An atlas of genetic influences on osteoporosis in humans and mice. <i>Nature Genetics</i> , 2019, 51, 258-266.	21.4	557
136	Long waiting time before tooth extraction may increase delayed wound healing in elderly Japanese. <i>Osteoporosis International</i> , 2019, 30, 621-628.	3.1	13
137	New therapeutic targets for osteoporosis. <i>Maturitas</i> , 2019, 120, 1-6.	2.4	44
138	Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports. <i>Osteoporosis International</i> , 2019, 30, 1111-1115.	3.1	26
139	Stopping Denosumab. <i>Current Osteoporosis Reports</i> , 2019, 17, 8-15.	3.6	77

#	ARTICLE	IF	CITATIONS
140	Efficacy, cost, and aspects to take into account in the treatment of osteoporosis in the elderly. <i>Revista Espanola De Geriatria Y Gerontologia</i> , 2019, 54, 156-167.	0.7	4
141	Recomendaciones de la Sociedad Española de Reumatología sobre osteoporosis. <i>Reumatología Clínica</i> , 2019, 15, 188-210.	0.5	40
142	European guidance for the diagnosis and management of osteoporosis in postmenopausal women. <i>Osteoporosis International</i> , 2019, 30, 3-44.	3.1	1,020
143	Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2019, 127, 117-135.	0.4	198
144	The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies. <i>Osteoporosis International</i> , 2019, 30, 71-78.	3.1	13
147	Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment. <i>Bone</i> , 2019, 120, 44-49.	2.9	19
148	Making sure the first osteoporotic fracture is also the last. <i>Joint Bone Spine</i> , 2020, 87, 9-11.	1.6	3
149	Bone Mineral Density After Transitioning From Denosumab to Alendronate. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e255-e264.	3.6	73
150	Histomorphometric analysis of bone remodeling. , 2020, , 445-467.		0
151	Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 153-159.	2.5	38
152	Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis. <i>Bone</i> , 2020, 130, 115121.	2.9	71
153	Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider. <i>Bone</i> , 2020, 130, 115150.	2.9	51
154	Osteoporosis: Current and Emerging Therapies Targeted to Immunological Checkpoints. <i>Current Medicinal Chemistry</i> , 2020, 27, 6356-6372.	2.4	54
155	Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism. <i>Nature Communications</i> , 2020, 11, 87.	12.8	118
156	Skeletal dynamics of Down syndrome: A developing perspective. <i>Bone</i> , 2020, 133, 115215.	2.9	18
157	Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?. <i>Osteoporosis International</i> , 2020, 31, 655-665.	3.1	30
158	Pharmacological mechanisms of therapeutics. , 2020, , 1689-1710.		1
159	Risk for Infections During Treatment With Denosumab for Osteoporosis: A Systematic Review and Meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1641-1658.	3.6	53

#	ARTICLE	IF	CITATIONS
160	Delayed Denosumab Injections and Bone Mineral Density Response: An Electronic Health Record-based Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1435-1444.	3.6	26
161	Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. <i>Osteoporosis International</i> , 2020, 31, 181-191.	3.1	35
162	Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1682-1699.	3.6	53
163	<p>A Review on the Role of Denosumab in Fracture Prevention</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 4029-4051.	4.3	30
164	New insight into unexpected bone formation by denosumab. <i>Drug Discovery Today</i> , 2020, 25, 1919-1922.	6.4	11
165	Inhibition of Autograft Bone Resorption by Antibone Resorptive Agents After Spinal Reconstruction Surgery for Extensive Cervical Chondrosarcoma: A Case Report with a 10-Year Follow-Up. <i>World Neurosurgery</i> , 2020, 142, 239-245.	1.3	1
166	Challenges in Preventing Bone Loss Induced by Aromatase Inhibitors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3122-3133.	3.6	10
167	The Belgian Bone Club 2020 guidelines for the management of osteoporosis in postmenopausal women. <i>Maturitas</i> , 2020, 139, 69-89.	2.4	41
168	Administration of Denosumab Preserves Bone Mineral Density at the Knee in Persons With Subacute Spinal Cord Injury: Findings From a Randomized Clinical Trial. <i>JBMR Plus</i> , 2020, 4, e10375.	2.7	23
169	Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment. <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 894-902.	2.7	21
170	Management of primary and secondary osteoporosis in children. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2096926.	2.7	25
172	Targeting the RANKL/RANK/OPG Axis for Cancer Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 1283.	2.8	42
173	Osteoporosis Therapeutics 2020. <i>Handbook of Experimental Pharmacology</i> , 2020, 262, 397-422.	1.8	13
174	Different fracture risk profile in patients treated with anti-osteoporotic drugs in real-life. <i>Reumatismo</i> , 2020, 72, 71-74.	0.9	7
175	Osteoimmunology: The Regulatory Roles of T Lymphocytes in Osteoporosis. <i>Frontiers in Endocrinology</i> , 2020, 11, 465.	3.5	29
176	Repurposing denosumab in lung cancer beyond counteracting the skeletal related events: an intriguing perspective. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1331-1346.	3.1	5
177	Atypical femur fractures: current understanding and approach to management. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2091698.	2.7	16
178	Failure of Oral Risedronate Therapy to Prevent Spontaneous Vertebral Fracture in a Patient Ceasing Denosumab: A Cautionary Case. <i>JBMR Plus</i> , 2020, 4, e10396.	2.7	4

#	ARTICLE	IF	CITATIONS
179	Smart Nanosacrificial Layer on the Bone Surface Prevents Osteoporosis through Acid-Base Neutralization Regulated Biocascade Effects. <i>Journal of the American Chemical Society</i> , 2020, 142, 17543-17556.	13.7	40
180	The combined effect of parathyroid hormone (1-34) and whole-body vibration exercise on physical performance in Osteoporotic women (PaVOS study): a secondary analysis from a randomised controlled trial. <i>BMC Sports Science, Medicine and Rehabilitation</i> , 2020, 12, 54.	1.7	0
181	Circulating Receptor Activator of Nuclear Factor κ B Ligand and triglycerides are associated with progression of lower limb arterial calcification in type 2 diabetes: a prospective, observational cohort study. <i>Cardiovascular Diabetology</i> , 2020, 19, 140.	6.8	12
182	Denosumab for cancer-related bone loss. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1261-1274.	3.1	12
183	A Simple-to-Use Score for Identifying Individuals at High Risk of Denosumab-Associated Hypocalcemia in Postmenopausal Osteoporosis: A Real-World Cohort Study. <i>Calcified Tissue International</i> , 2020, 107, 567-575.	3.1	6
184	Bisphosphonate and denosumab initiation in older adults in Ontario, Canada: a population-based cohort study. <i>Archives of Osteoporosis</i> , 2020, 15, 133.	2.4	5
185	Glucocorticoid-Induced Osteoporosis: The Potential Role of Romosozumab. <i>Journal of Clinical Rheumatology and Immunology</i> , 2020, 20, 71-79.	0.4	0
186	Synergistic use of biomaterials and licensed therapeutics to manipulate bone remodelling and promote non-union fracture repair. <i>Advanced Drug Delivery Reviews</i> , 2020, 160, 212-233.	13.7	19
187	American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update. <i>Endocrine Practice</i> , 2020, 26, 1-46.	2.1	493
188	Differential Osteoprotegerin Kinetics after Stimulation with Desmopressin and Lipopolysaccharides In Vivo. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1108-1115.	3.4	6
189	Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation. <i>Bone Reports</i> , 2020, 12, 100267.	0.4	22
191	Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1858-1870.	2.8	63
192	Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 325.	3.7	40
193	Pharmacological treatment for managing bone health in axial spondyloarthritis: systematic review and meta-analysis. <i>Rheumatology International</i> , 2020, 40, 1369-1384.	3.0	7
194	Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study. <i>BMC Women's Health</i> , 2020, 20, 48.	2.0	7
195	Remarkable loss of bone mineral density in 6 months after denosumab discontinuation: a case report. <i>Modern Rheumatology Case Reports</i> , 2020, 4, 218-221.	0.7	1
196	Reply to E. Gonzalez-Rodriguez et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 1642-1643.	1.6	0
197	Modeling-Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1282-1288.	2.8	30

#	ARTICLE	IF	CITATIONS
198	Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis. <i>Expert Review of Endocrinology and Metabolism</i> , 2020, 15, 283-298.	2.4	24
199	Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches. <i>Bone</i> , 2020, 139, 115516.	2.9	44
200	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1784-1802.	2.0	14
201	Therapeutic approach and management algorithms in medication-related osteonecrosis of the jaw (MONJ): recommendations of a multidisciplinary group of experts. <i>Archives of Osteoporosis</i> , 2020, 15, 101.	2.4	11
202	Cellular Communication in Bone Homeostasis and the Related Anti-osteoporotic Drug Development. <i>Current Medicinal Chemistry</i> , 2020, 27, 1151-1169.	2.4	18
203	Estimation of Long-term Efficacy of Denosumab Treatment in Postmenopausal Women With Osteoporosis: A FRAX and Virtual Twin-Based Post Hoc Analysis From the FREEDOM and FREEDOM Extension Trials. <i>JBMR Plus</i> , 2020, 4, e10348.	2.7	3
204	Modulation of bone turnover aberration: A target for management of primary osteoporosis in experimental rat model. <i>Heliyon</i> , 2020, 6, e03341.	3.2	9
205	Favorable skeletal benefit/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed. <i>Bone</i> , 2020, 134, 115287.	2.9	14
206	Tooth extractions in patients under antiresorptive therapy for osteoporosis: Primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet-rich fibrin for the prevention of antiresorptive agent-related osteonecrosis of the jaw. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2020, 48, 444-451.	1.7	16
207	Denosumab in postmenopausal women with osteoporosis and diabetes: Subgroup analysis of FREEDOM and FREEDOM extension. <i>Bone</i> , 2020, 134, 115268.	2.9	41
208	Advances in Models of Fibrous Dysplasia/McCune-Albright Syndrome. <i>Frontiers in Endocrinology</i> , 2019, 10, 925.	3.5	12
209	Emerging therapeutic targets for osteoporosis. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 115-130.	3.4	16
210	A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1207-1215.	2.8	64
211	The crisis of inadequate treatment in osteoporosis. <i>Lancet Rheumatology</i> , The, 2020, 2, e110-e119.	3.9	25
212	Reduced Bone Modeling and Unbalanced Bone Remodeling: Targets for Antiresorptive and Anabolic Therapy. <i>Handbook of Experimental Pharmacology</i> , 2020, 262, 423-450.	1.8	7
213	The epidemiology of osteoporosis. <i>British Medical Bulletin</i> , 2020, 133, 105-117.	6.9	212
214	The association between renal function and BMD response to bisphosphonate treatment: Real-world cohort study using linked national registers. <i>Bone</i> , 2020, 137, 115371.	2.9	8
215	Zoledronate Following Denosumab Discontinuation: Partial Reassurance but No Confidence. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1205-1206.	2.8	6

#	ARTICLE	IF	CITATIONS
216	Overview of treatment approaches to osteoporosis. <i>British Journal of Pharmacology</i> , 2021, 178, 1891-1906.	5.4	83
217	Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials. <i>Osteoporosis International</i> , 2021, 32, 413-424.	3.1	6
218	Cardiovascular Safety of Denosumab Across Multiple Indications: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 24-40.	2.8	14
219	RANKL as a target for the treatment of osteoporosis. <i>Journal of Bone and Mineral Metabolism</i> , 2021, 39, 91-105.	2.7	37
220	Epigenetic therapies of osteoporosis. <i>Bone</i> , 2021, 142, 115680.	2.9	11
221	Medication-related osteonecrosis and osteoradionecrosis of the jaws: Update and current management. <i>Morphologie</i> , 2021, 105, 170-187.	0.9	13
222	Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 397-409.	3.6	43
223	Senile and Postmenopausal Osteoporosis: Pathophysiology, Diagnosis, and Treatment. , 2021, , 131-169.		3
224	Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough. <i>Journal of Clinical Densitometry</i> , 2021, 24, 338-340.	1.2	9
225	Ameliorative effects of Osteo-F, a newly developed herbal formula, on osteoporosis via activation of bone formation. <i>Journal of Ethnopharmacology</i> , 2021, 268, 113590.	4.1	4
226	Serum MicroRNA Differences Between Fracture in Postmenopausal Women with and without Diabetes. <i>Orthopaedic Surgery</i> , 2021, 13, 285-295.	1.8	1
227	The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learn. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 191-213.	2.4	3
228	Denosumab induced atypical fracture of free vascularized fibular graft 20 years after tumour reconstruction. <i>ANZ Journal of Surgery</i> , 2021, 91, E335-E337.	0.7	0
229	Same-side insufficiency fractures of the tibia and femur after denosumab discontinuation: a case report. <i>Modern Rheumatology Case Reports</i> , 2021, 5, 178-181.	0.7	1
230	Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 264-281.	3.6	132
231	Inhibition of the RANKL with denosumab has no effect on circulating markers of atherosclerosis in women with postmenopausal osteoporosis: a pilot study. <i>Endocrine</i> , 2021, 71, 199-207.	2.3	7
232	The role of M1 and M2 macrophage polarization in progression of medication-related osteonecrosis of the jaw. <i>Clinical Oral Investigations</i> , 2021, 25, 2845-2857.	3.0	23
233	Three-year results of denosumab treatment for osteoporosis in women with rheumatoid arthritis and primary osteoporosis: A clinical observational study. <i>Modern Rheumatology</i> , 2021, 31, 600-606.	1.8	6

#	ARTICLE	IF	CITATIONS
234	Romozosumab for the treatment of postmenopausal osteoporosis. , 2021, , 1827-1833.		0
235	Long-term treatment strategies and goal-directed therapy. , 2021, , 1867-1872.		2
236	Potential protective effect of zoledronic acid when switching from long-term therapy of osteoporosis with denosumab. Meditsinskiy Sovet, 2021, , 185-191.	0.5	1
237	Fracture rates in patients discontinuing alendronate treatment in real life: a population-based cohort study. Osteoporosis International, 2021, 32, 1103-1115.	3.1	10
238	Lessons from bone histomorphometry on the mechanisms of action of osteoporosis drugs. , 2021, , 1835-1863.		2
239	Bone Loss. , 2021, , 237-249.		0
240	Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review. Journal of Clinical Medicine, 2021, 10, 152.	2.4	89
241	Epigenetics of Aging and Aging-Associated Diseases. International Journal of Molecular Sciences, 2021, 22, 401.	4.1	110
242	On the evolution and contemporary roles of bone remodeling. , 2021, , 727-772.		1
243	Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation. Calcified Tissue International, 2021, 108, 587-594.	3.1	8
244	Pharmacological osteonecrosis in maxillofacial surgery, period 2013-2019. Revista De La Sociedad Espanola Del Dolor, 2021, 28, .	0.1	1
245	Risk factors of the poor long-term prognosis of osteoporotic vertebral fractures: A multicenter cohort study. Journal of Orthopaedic Surgery, 2021, 29, 230949902199496.	1.0	0
246	Management of bone health in men with prostate cancer. , 2021, , 1407-1419.		0
247	Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study. Journal of Bone and Mineral Metabolism, 2021, 39, 463-473.	2.7	10
248	The Effect of Teriparatide for the Treatment of Multiple Spontaneous Clinical Vertebral Fractures after Discontinuation of Denosumab in a Female Patient with Rheumatoid Arthritis: A Case Report. Tohoku Journal of Experimental Medicine, 2021, 254, 57-61.	1.2	4
249	Bisphosphonate und Denosumab. , 2021, , 205-223.		0
250	Should denosumab treatment for osteoporosis be continued indefinitely?. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110100.	3.2	7
251	Osteoporosis associated with gastrointestinal disorders: celiac and inflammatory bowel diseases. , 2021, , 1069-1082.		0

#	ARTICLE	IF	CITATIONS
252	Denosumab for the treatment of osteoporosis. , 2021, , 1737-1755.		1
253	Evaluation and management of atypical femoral fractures: an update of current knowledge. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2021, 31, 825-840.	1.4	7
254	Effect of denosumab switched from bisphosphonates in preventing joint destruction in postmenopausal rheumatoid arthritis patients with anti-cyclic citrullinated peptide antibodies. <i>Journal of Orthopaedic Surgery and Research</i> , 2021, 16, 107.	2.3	11
255	Osteoporosis Treatment with Anti-Sclerostin Antibodiesâ€™ Mechanisms of Action and Clinical Application. <i>Journal of Clinical Medicine</i> , 2021, 10, 787.	2.4	32
256	Denosumab Treatment for Giant Cell Tumors, Aneurysmal Bone Cysts, and Fibrous Dysplasiaâ€™ Risks and Benefits. <i>Current Osteoporosis Reports</i> , 2021, 19, 141-150.	3.6	16
257	The prevention of osteoporosis and sarcopenia in older adults. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1388-1398.	2.6	42
258	The comparative efficiency of denosumab treatment in patients with postmenopausal osteoporosis, primary hyperparathyroidism and glucocorticoid-induced osteoporosis in real clinical practice. <i>Osteoporosis and Bone Diseases</i> , 2021, 23, 4-13.	1.4	6
259	Summary of the draft federal clinical guidelines for osteoporosis. <i>Osteoporosis and Bone Diseases</i> , 2021, 23, 4-21.	1.4	14
260	Fragility fracture identifies patients at imminent risk for subsequent fracture: real-world retrospective database study in Ontario, Canada. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 224.	1.9	23
261	Physiological and Pharmacological Roles of PTH and PTHrP in Bone Using Their Shared Receptor, PTH1R. <i>Endocrine Reviews</i> , 2021, 42, 383-406.	20.1	41
262	Efficacy of Denosumab Therapy Following Treatment with Bisphosphonates in Women with Osteoporosis: A Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1728.	2.6	2
263	Duration-Dependent Increase of Human Bone Matrix Mineralization in Long-Term Bisphosphonate Users with Atypical Femur Fracture. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1031-1041.	2.8	9
264	Long-Term Follow-Up of Denosumab Discontinuers with Multiple Vertebral Fractures in the Real-World: A Case Series. <i>Hormone and Metabolic Research</i> , 2021, 53, 185-190.	1.5	2
265	Persistence with Denosumab in Women at High Risk of Fracture in Bulgaria. <i>Rheumatology and Therapy</i> , 2021, 8, 443-455.	2.3	0
266	Effects of denosumab on rheumatic diseases and refractory glucocorticoid-induced osteoporosis: a prospective study. <i>Archives of Osteoporosis</i> , 2021, 16, 39.	2.4	4
267	Adverse events associated with bone-directed therapies in patients with cancer. <i>Bone</i> , 2022, 158, 115901.	2.9	7
268	Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1900-1907.	0.7	21
269	Effectiveness and safety of percutaneous kyphoplasty combined with zoledronic acid in treatment of osteoporotic vertebral compression fractures: a meta-analysis. <i>Archives of Orthopaedic and Trauma Surgery</i> , 2021, , 1.	2.4	1

#	ARTICLE	IF	CITATIONS
270	Effect of denosumab on osteolytic lesion activity after total hip arthroplasty: a single-centre, randomised, double-blind, placebo-controlled, proof of concept trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e195-e203.	3.9	7
271	SIRT1, a promising regulator of bone homeostasis. <i>Life Sciences</i> , 2021, 269, 119041.	4.3	38
272	Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study. <i>Bone</i> , 2021, 144, 115830.	2.9	27
273	The effect of denosumab on pedicle screw fixation: a prospective 2-year longitudinal study using finite element analysis. <i>Journal of Orthopaedic Surgery and Research</i> , 2021, 16, 219.	2.3	10
274	Denosumab Recovers Aortic Arch Calcification During Long-Term Hemodialysis. <i>Kidney International Reports</i> , 2021, 6, 605-612.	0.8	20
275	Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview. <i>Journal of Clinical Medicine</i> , 2021, 10, 1241.	2.4	25
276	Denosumab: seguimiento y duraci3n del tratamiento. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2021, 28, 184-190.	0.0	0
277	Special Considerations to Improve Clinical Outcomes in Patients with Osteoporosis Undergoing Spine Surgery. <i>International Journal of Spine Surgery</i> , 2021, 15, 386-401.	1.5	7
278	Ten4Year Simulation of the Effects of Denosumab on Bone Remodeling in Human Biopsies. <i>JBMR Plus</i> , 2021, 5, e10494.	2.7	10
279	Is denosumab associated with an increased risk for infection in patients with low bone mineral density? A systematic review and meta4analysis of randomized controlled trials. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 869-879.	1.9	2
280	Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1225-1234.	2.8	14
281	A cautionary case: osteoporotic femur fracture after robotic-assisted total knee arthroplasty. <i>Osteoporosis International</i> , 2021, 32, 2125-2129.	3.1	5
282	Vaccination for Coronavirus Disease 2019 (COVID-19) and Relationship to Osteoporosis Care: Current Evidence and Suggested Approaches. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1042-1047.	2.8	14
283	Letter to the Editor From Zhu and Briganti: 4Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease4. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2833-e2834.	3.6	0
284	The Impact of COVID-19 on the Optimal Management of Osteoporosis. <i>Journal of Bone Metabolism</i> , 2021, 28, 115-122.	1.3	8
285	High persistence over two years with denosumab among postmenopausal women with osteoporosis in France: A prospective cohort study. <i>Bone</i> , 2021, 146, 115890.	2.9	1
286	Update on Approved Osteoporosis Therapies Including Combination and Sequential Use of Agents. <i>Endocrinology and Metabolism Clinics of North America</i> , 2021, 50, 179-191.	3.2	6
288	Antiresorptive and anabolic medications used in the perioperative period of patients with osteoporosis undergoing spine surgery: their impact on the biology of fusion and systematic review of the literature. <i>Neurosurgical Focus</i> , 2021, 50, E13.	2.3	7

#	ARTICLE	IF	CITATIONS
290	Analysis of bone architecture using fractal-based TX-Analyzer [®] in adult patients with osteogenesis imperfecta. <i>Bone</i> , 2021, 147, 115915.	2.9	1
291	Celastrol Attenuates RANKL-Induced Osteoclastogenesis in vitro and Reduces Titanium Particle-Induced Osteolysis and Ovariectomy-Induced Bone Loss in vivo. <i>Frontiers in Pharmacology</i> , 2021, 12, 682541.	3.5	6
292	Long-Term Treatment of Postmenopausal Osteoporosis. <i>Endocrinology and Metabolism</i> , 2021, 36, 544-552.	3.0	34
293	Spleen tyrosine kinase (SYK) inhibitor PRT062607 protects against ovariectomy-induced bone loss and breast cancer-induced bone destruction. <i>Biochemical Pharmacology</i> , 2021, 188, 114579.	4.4	4
294	Osteoporosis treatment in patients undergoing spinal fusion: a systematic review and meta-analysis. <i>Neurosurgical Focus</i> , 2021, 50, E9.	2.3	15
295	Analysis of the subsequent treatment of osteoporosis by transitioning from bisphosphonates to denosumab, using quantitative computed tomography: A prospective cohort study. <i>Bone Reports</i> , 2021, 14, 101090.	0.4	3
296	Dual targeting of salt inducible kinases and CSF1R uncouples bone formation and bone resorption. <i>ELife</i> , 2021, 10, .	6.0	12
297	Denosumab Discontinuation in Patients Treated for Low Bone Density and Osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2021, 50, 205-222.	3.2	8
298	Osteoporosis in older people. <i>Journal of Pharmacy Practice and Research</i> , 2021, 51, 265-274.	0.8	2
299	Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1729-1738.	2.8	23
300	Denosumab-induced hypocalcemia in a patient with hyperthyroidism: a case report. <i>Osteoporosis International</i> , 2022, 33, 305-308.	3.1	3
301	Retrospective Analysis of the Effects of Non-Compliance with Denosumab on Changes in Bone Mineral Density During the COVID-19 Pandemic. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 1579-1584.	1.8	6
302	Multiple rebound-associated vertebral fractures after denosumab discontinuation: is prompt antiresorptive therapy always recommended, even when the risk of fracture seems low? A case report. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2021, 21, .	1.2	2
303	The Treatment Gap in Osteoporosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3002.	2.4	34
304	Recent Progresses in the Treatment of Osteoporosis. <i>Frontiers in Pharmacology</i> , 2021, 12, 717065.	3.5	28
305	Rethinking of osteoporosis through a sex- and gender-informed approach in the COVID-19 era. <i>Minerva Obstetrics and Gynecology</i> , 2021, 73, .	1.0	2
306	Risks vs. benefits of switching therapy in patients with postmenopausal osteoporosis. <i>Expert Review of Endocrinology and Metabolism</i> , 2021, 16, 217-228.	2.4	2
307	Diagnostic, treatment, and follow-up of osteoporosis – position statement of the Latin American Federation of Endocrinology. <i>Archives of Osteoporosis</i> , 2021, 16, 114.	2.4	5

#	ARTICLE	IF	CITATIONS
308	Osteoporosis and fractures in women: the burden of disease. <i>Climacteric</i> , 2022, 25, 4-10.	2.4	71
310	New Insights Into Osteoclast Biology. <i>JBMR Plus</i> , 2021, 5, e10539.	2.7	45
311	Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis. <i>Journal of Orthopaedic Surgery and Research</i> , 2021, 16, 533.	2.3	62
312	Long-term persistence with denosumab: real-world data from the Austrian Osteoporosis Clinic (AOC). A retrospective data analysis. <i>Osteoporosis International</i> , 2022, 33, 263-272.	3.1	7
313	Osteoanabolic therapy for osteoporosis in women. <i>Climacteric</i> , 2022, 25, 60-66.	2.4	7
314	Preventing Rebound-Associated Fractures after Discontinuation of Denosumab Therapy: A Position Statement from the Health Insurance Committee of the Korean Endocrine Society. <i>Endocrinology and Metabolism</i> , 2021, 36, 909-911.	3.0	6
315	Menopausal osteoporosis in the practice of a gynecologist. <i>Meditinskiy Sovet</i> , 2021, , 320-331.	0.5	0
316	Osteoporosis therapies and their mechanisms of action (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1379.	1.8	34
317	Update on bone health: the International Menopause Society White Paper 2021. <i>Climacteric</i> , 2021, 24, 498-504.	2.4	7
319	Update on Osteoporosis Screening and Management. <i>Medical Clinics of North America</i> , 2021, 105, 1117-1134.	2.5	79
320	Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment. <i>Kidney International</i> , 2021, 100, 546-558.	5.2	39
321	Markov Models for Economic Evaluation in Osteoporosis Treatment. <i>Mathematics</i> , 2021, 9, 2331.	2.2	0
322	Aspects of intercellular communication in bone and implications in therapy. <i>Bone</i> , 2021, 153, 116148.	2.9	2
323	Denosumab-induced osteonecrosis of external auditory canal. <i>Auris Nasus Larynx</i> , 2021, 48, 1199-1203.	1.2	5
324	Bilateral atypical fractures of the femur: Ten years AFTER ten years of bisphosphonate therapy. <i>Bone Reports</i> , 2021, 15, 101112.	0.4	1
325	RANKL and RANK in extracellular vesicles: surprising new players in bone remodeling. , 2021, 2, 18-28.		11
326	Anti-resorptive Therapies. , 2021, , 67-80.		0
327	The modulatory effect and implication of gut microbiota on osteoporosis: from the perspective of "gut-brain-gut" bone-axis. <i>Food and Function</i> , 2021, 12, 5703-5718.	4.6	37

#	ARTICLE	IF	CITATIONS
328	Modified Quinoxaline-Fused Oleanolic Acid Derivatives as Inhibitors of Osteoclastogenesis and Potential Agent in Anti-Osteoporosis. <i>ChemistrySelect</i> , 2020, 5, 1526-1533.	1.5	7
329	Efficacy and Safety of Osteoporosis Treatment. , 2019, , 43-57.		2
330	Osteoporosis in Men. <i>Contemporary Endocrinology</i> , 2020, , 391-406.	0.1	1
331	Basic Aspects of Bone Mineralization. <i>Contemporary Endocrinology</i> , 2020, , 89-113.	0.1	3
332	Magnetic resonance imaging has an advantage over conventional spine X-rays in the evaluation of rebound-associated vertebral fractures following denosumab discontinuation. <i>Endocrine</i> , 2020, 69, 516-518.	2.3	7
334	Advances in the occurrence and biotherapy of osteoporosis. <i>Biochemical Society Transactions</i> , 2020, 48, 1623-1636.	3.4	42
335	Treatment options for glucocorticoid-induced osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 721-732.	1.8	25
336	Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment. <i>Journal of Bone Metabolism</i> , 2019, 26, 213.	1.3	22
338	Management of atypical femoral fracture in a patient with osteogenesis imperfecta. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-221835.	0.5	4
339	Treatment of Osteoporosis, with a Focus on 2 Monoclonal Antibodies. <i>Medical Science Monitor</i> , 2018, 24, 8758-8766.	1.1	13
340	Treatment of patients with osteoporosis: issues of therapy duration, adherence, and replacement. <i>Sovremennaya Revmatologiya</i> , 2018, 12, 59-64.	0.5	2
341	Novel therapies in osteoporosis: PTH-related peptide analogs and inhibitors of sclerostin. <i>Journal of Molecular Endocrinology</i> , 2019, 62, R145-R154.	2.5	28
342	Can Denosumab be used in combination with Doxorubicin in Osteosarcoma?. <i>Oncotarget</i> , 2020, 11, 2763-2773.	1.8	9
343	Prevention and treatment of oral adverse effects of antiresorptive medications for osteoporosis – A position paper of the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Stomatology and Oral Pathology (Sobep), and Brazilian Association for Bone Evaluation and Osteometabolism (Abrasso). <i>Archives of Endocrinology and Metabolism</i> . 2020, . .	0.6	2
344	Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2020, 24, 1-314.	2.8	82
345	Effects of denosumab treatment in chronic liver disease patients with osteoporosis. <i>World Journal of Gastroenterology</i> , 2020, 26, 4960-4971.	3.3	13
346	Bisphosphonate-related atypical femoral fracture: Managing a rare but serious complication. <i>Cleveland Clinic Journal of Medicine</i> , 2018, 85, 885-893.	1.3	21
347	Bone Cell Communication Factors Provide a New Therapeutic Strategy for Osteoporosis. <i>Chonnam Medical Journal</i> , 2020, 56, 94.	0.9	11

#	ARTICLE	IF	CITATIONS
348	Denosumab (RANKL Inhibitor): A Potent Anti-Resorptive Agent. Journal of the Korean Fracture Society, 2021, 34, 142.	0.1	0
349	Osteogenesis Imperfecta: Current and Prospective Therapies. Biomolecules, 2021, 11, 1493.	4.0	27
350	A Novel Case Study of the Use of Real-World Evidence to Support the Registration of an Osteoporosis Product in China. Therapeutic Innovation and Regulatory Science, 2022, 56, 137-144.	1.6	8
351	Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan. Archives of Osteoporosis, 2021, 16, 155.	2.4	7
352	Review and Update of the Risk Factors and Prevention of Antiresorptive-Related Osteonecrosis of the Jaw. Endocrinology and Metabolism, 2021, 36, 917-927.	3.0	9
353	Osteoporosis and quality of bone. Vnitřní Lekarství, 2018, 64, 197-208.	0.2	0
354	Recent Update on RANKL Inhibitor. Korean Journal of Medicine, 2018, 93, 252-259.	0.3	1
355	Vitamin D, Inflammation and Osteoporosis in Rheumatoid Arthritis. Open Rheumatology Journal, 2018, 12, 300-312.	0.2	4
356	Management of Patients with Increased Fracture Risk. , 2019, , 59-70.		0
357	Bone Health in Patients with Breast Cancer. Oncology & Hematology Review, 2019, 15, 16.	0.2	1
358	Comparative evaluation of denosumab efficacy of in patients with rheumatoid arthritis and postmenopausal osteoporosis: results of 1-year study in clinical practice. Nauchno-Prakticheskaya Revmatologiya, 2019, 57, 160-165.	1.0	2
360	Calcium and Metabolic Bone Disorders. , 0, , .		0
361	Current and Emerging Treatment of Osteoporosis. Practical Issues in Geriatrics, 2021, , 257-272.	0.8	6
362	New Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach. Molecules, 2021, 26, 6491.	3.8	2
363	The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density. Drugs, 2021, 81, 1831-1858.	10.9	18
365	Antiresorptive Therapy for Osteoporosis. , 2021, , 123-134.		0
366	Denosumab: Mechanisms and Therapeutic Effects in the Treatment of Osteoporosis. Contemporary Endocrinology, 2020, , 309-322.	0.1	1
367	Osteoporosis, Glucocorticoid-Related Osteoporosis and Glucocorticoid Withdrawal Regimen. , 2020, , 95-107.		0

#	ARTICLE	IF	CITATIONS
369	Comparison of the Effects of Native Vitamin D and Eldecalcitol on Muscular Strength and Dynamic Balance in Patients with Postmenopausal Osteoporosis. <i>Progress in Rehabilitation Medicine</i> , 2020, 5, n/a.	0.9	3
370	Cardiovascular disorders in patients with primary hyperparathyroidism according to registry data. <i>Profilakticheskaya Meditsina</i> , 2020, 23, 26.	0.6	3
371	Response to Letter to the Editor. <i>Journal of Oral and Maxillofacial Surgery</i> , 2022, 80, 205-206.	1.2	0
372	Benefits of the Phytoestrogen Resveratrol for Perimenopausal Women. <i>Endocrines</i> , 2021, 2, 457-471.	1.0	2
373	Metabolic Bone Disease and Osteoporosis. , 2022, , 119-146.		0
374	Dosing interval adjustment of denosumab for the treatment of giant cell tumor of the sphenoid bone: A case report. , 2020, 11, 370.		2
375	Real World Experience of Denosumab Treatment in the Belfast Osteoporosis Service. <i>Ulster Medical Journal</i> , 2019, 88, 150-156.	0.2	0
376	Changes in peripheral monocyte populations 48-72 hours after subcutaneous denosumab administration in women with osteoporosis. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2020, 20, 339-346.	0.1	1
377	Calcitonin: A useful old friend. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2020, 20, 600-609.	0.1	6
379	Experience of long-term use of denosumab in women with osteoporosis and various concomitant diseases. <i>Osteoporosis and Bone Diseases</i> , 2021, 24, 48-55.	1.4	0
380	Calcium and bone metabolism. , 2022, , 499-564.		0
381	Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review. <i>Advances in Therapy</i> , 2022, 39, 58-74.	2.9	49
382	Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. <i>Osteoporosis and Bone Diseases</i> , 2021, 24, 4-47.	1.4	43
383	Interstitial lung disease in a woman with rheumatoid arthritis treated with denosumab: A case report. <i>Modern Rheumatology Case Reports</i> , 2022, 6, 155-159.	0.7	3
384	ESTIMATION OF PERIODONTAL MICROCIRCULATION, JAW AFTER INJECTION OF ANTI-RESORPTIVE DRUG IN EXPERIMENT. <i>The Actual Problems in Dentistry</i> , 2021, 17, 69-76.	0.3	1
385	Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 340-348.	2.8	48
386	ULK1 Suppresses Osteoclast Differentiation and Bone Resorption via Inhibiting Syk-JNK through DOK3. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-17.	4.0	7
387	The current situation in the approach to osteoporosis in older adults in Turkey: areas in need of improvement with a model for other populations. <i>Archives of Osteoporosis</i> , 2021, 16, 179.	2.4	2

#	ARTICLE	IF	CITATIONS
388	Bone Minimodeling, Modeling-Based Bone Formation in Trabecular, Endocortical and Periosteal Bone. , 2022, , 67-87.		0
389	Denosumab in the Treatment of Postmenopausal Women with Osteoporosis: Fracture Outcomes, BMD, and Morphological Assessment. , 2022, , 377-388.		0
391	Bone Remodeling and Modeling: Therapeutic Targets for the Treatment of Osteoporosis. , 2022, , 111-128.		0
392	Current Treatment of Osteoporosis and Future Prospects. , 2022, , 441-455.		0
393	Effect of Denosumab in Primary Osteoporosis Patients According to Their Bisphosphonate Response. Journal of Korean Society of Spine Surgery, 2021, 28, 116.	0.0	0
394	Therapeutic efficacy of denosumab for rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology Advances in Practice, 2021, 5, rkab099.	0.7	5
396	The Efficacy of Denosumab in Patients With Rheumatoid Arthritis: A Systematic Review and Pooled Analysis of Randomized or Matched Data. Frontiers in Immunology, 2021, 12, 799575.	4.8	11
398	Denosumab for the treatment of osteoporosis. Aging Pathobiology and Therapeutics, 2020, 2, 168-170.	0.5	1
400	Kidney Function Change and All-Cause Mortality in Denosumab Users with and without Chronic Kidney Disease. Journal of Personalized Medicine, 2022, 12, 185.	2.5	2
401	Antibody Treatment and Osteoporosis: Clinical Perspective. Springer Series in Biomaterials Science and Engineering, 2022, , 111-126.	1.0	0
404	Stop the denosumab delay! The effect of implementing an automatic reminder in the electronic medical record. Archives of Osteoporosis, 2022, 17, 18.	2.4	0
405	Real-World Effectiveness of Anti-Resorptive Treatment in Patients With Incident Fragility Fracturesâ€”The STORM Cohortâ€”A Swedish Retrospective Observational Study. Journal of Bone and Mineral Research, 2020, 37, 649-659.	2.8	2
406	Osteosarcoma tumor microenvironment: the key for the successful development of biologically relevant 3D in vitro models. In Vitro Models, 2022, 1, 5-27.	2.0	9
407	Mechanical force promotes dimethylarginine dimethylaminohydrolase 1-mediated hydrolysis of the metabolite asymmetric dimethylarginine to enhance bone formation. Nature Communications, 2022, 13, 50.	12.8	7
408	The Efficacy of Alendronate Versus Denosumab on Major Osteoporotic Fracture Risk in Elderly Patients With Diabetes Mellitus: A Danish Retrospective Cohort Study. Frontiers in Endocrinology, 2021, 12, 826997.	3.5	4
409	Bone health 2022: an update. Climacteric, 2022, 25, 1-3.	2.4	16
410	New national osteoporosis guidanceâ€”implications for geriatricians. Age and Ageing, 2022, 51, .	1.6	3
411	The effect of osteoporosis treatment on bone mass. Best Practice and Research in Clinical Endocrinology and Metabolism, 2022, 36, 101623.	4.7	7

#	ARTICLE	IF	CITATIONS
412	Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. <i>Journal of Bone Metabolism</i> , 2021, 28, 279-296.	1.3	18
413	Microfibrillar-associated protein 5 regulates osteogenic differentiation by modulating the Wnt/ β^2 -catenin and AMPK signaling pathways. <i>Molecular Medicine</i> , 2021, 27, 153.	4.4	6
414	Medication-related osteonecrosis of the jaw: An update. <i>National Journal of Maxillofacial Surgery</i> , 2022, 13, 5.	0.5	9
417	Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis. <i>Calcified Tissue International</i> , 2022, 111, 47-55.	3.1	10
418	Role of Dietary Supplements and Probiotics in Modulating Microbiota and Bone Health: The Gut-Bone Axis. <i>Cells</i> , 2022, 11, 743.	4.1	36
419	Temporary Denosumab Discontinuation Promotes Bone Healing of Osteonecrosis of the Jaw and Minimizes the Invasiveness of Surgery: A Case Presentation. <i>Oral</i> , 2022, 2, 41-48.	0.6	1
420	American Association of Oral and Maxillofacial Surgeons™ Position Paper on Medication-Related Osteonecrosis of the Jaws™ 2022 Update. <i>Journal of Oral and Maxillofacial Surgery</i> , 2022, 80, 920-943.	1.2	312
421	Bone Mineral and Organic Properties in Postmenopausal Women Treated With Denosumab for Up to 10 years. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 856-864.	2.8	8
422	Management of patients at very high risk of osteoporotic fractures through sequential treatments. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 695-714.	2.9	33
423	Drug therapy for osteoporosis in older adults. <i>Lancet, The</i> , 2022, 399, 1080-1092.	13.7	193
424	Bone mass gains after one denosumab injection followed by zoledronate. <i>Journal of Clinical Densitometry</i> , 2022, , .	1.2	1
425	How to Treat Osteoporosis in Octogenarians?. <i>European Journal of Geriatrics and Gerontology</i> , 2022, 4, 114-118.	0.2	1
426	UK clinical guideline for the prevention and treatment of osteoporosis. <i>Archives of Osteoporosis</i> , 2022, 17, 58.	2.4	146
427	Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women. <i>Osteoporosis International</i> , 2022, 33, 1591-1599.	3.1	11
428	Multidisciplinary management of osteoporotic vertebral fractures. <i>Minerva Endocrinology</i> , 2022, 47, .	1.1	6
429	Predictive factors for achievement of treatment goals in patients with postmenopausal osteoporosis treated with denosumab. <i>Modern Rheumatology</i> , 2023, 33, 217-223.	1.8	3
430	Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1441-1460.	3.6	35
431	Giant Cell Tumor of Bone: Effect of Longer Dosing Intervals of Denosumab on Tumor Control and Bone-related Complications. <i>Oncologist</i> , 2022, 27, 595-599.	3.7	9

#	ARTICLE	IF	CITATIONS
432	Multiple idiopathic external cervical root resorption in patient treated continuously with denosumab: a case report. <i>BMC Oral Health</i> , 2022, 22, 129.	2.3	6
433	Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature. <i>Endocrinology and Metabolism</i> , 2022, 37, 183-194.	3.0	2
434	Impaction Bone Grafting Combined with Titanium Mesh for Acetabular Bone Defects Reconstruction in Total Hip Arthroplasty Revision: A Retrospective and Mini-Review Study. <i>Orthopaedic Surgery</i> , 2022, , .	1.8	0
435	RANKL regulates testicular cancer growth and Denosumab treatment has suppressive effects on GCNIS and advanced seminoma. <i>British Journal of Cancer</i> , 2022, 127, 408-421.	6.4	2
436	Evaluating the Effect of Denosumab in Preventing Anchorage Loss: A Split-mouth Randomized Controlled Trial. <i>Journal of Contemporary Dental Practice</i> , 2022, 22, 1399-1405.	0.5	0
437	The Impact of COVID-19 in Bone Metabolism: Basic and Clinical Aspects. <i>Hormone and Metabolic Research</i> , 2022, 54, 540-548.	1.5	4
438	When and how to stop denosumab therapy in a patient with osteoporosis. <i>Clinical Endocrinology</i> , 2023, 98, 649-653.	2.4	2
440	The clinician's guide to prevention and treatment of osteoporosis. <i>Osteoporosis International</i> , 2022, 33, 2049-2102.	3.1	255
441	Pharmacological treatment of osteoporosis: 2022 update. <i>Journal of the Korean Medical Association</i> , 2022, 65, 241-248.	0.3	3
442	Soy-whey Dual-protein Alleviates Osteoporosis of Ovariectomized Rats via Regulating Bone Fat Metabolism through Gut-Liver-Bone Axis. <i>Nutrition</i> , 2022, , 111723.	2.4	4
443	Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence. <i>Cancers</i> , 2022, 14, 2290.	3.7	12
444	Guideline No. 422g: Menopause and Osteoporosis. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2022, 44, 527-536.e5.	0.7	5
445	Directive clinique no 422g : Ménopause et ostéoporose. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2022, 44, 537-546.e5.	0.7	0
447	Management of Postmenopausal Osteoporosis. <i>Obstetrics and Gynecology</i> , 2022, 139, 698-717.	2.4	14
448	Meta-Analysis of Two Human RNA-seq Datasets to Determine Periodontitis Diagnostic Biomarkers and Drug Target Candidates. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5580.	4.1	6
449	Incidence and risk factors associated to Medication-Related Osteo Necrosis of the Jaw (MRONJ) in patients with osteoporosis after tooth extractions. A 12-months observational cohort study. <i>Journal of Stomatology, Oral and Maxillofacial Surgery</i> , 2022, 123, 616-621.	1.3	4
450	Recomendaciones de la Sociedad Española de Nefrología para el manejo de las alteraciones del metabolismo óseo-mineral en los pacientes con enfermedad renal crónica: 2021 (SEN-MM). <i>Nefrología</i> , 2022, 42, 1-37.	0.4	8
451	Osteoimmunology: The correlation between osteoclasts and the Th17/Treg balance in osteoporosis. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 3591-3597.	3.6	16

#	ARTICLE	IF	CITATIONS
452	A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients. <i>Scientific Reports</i> , 2022, 12, .	3.3	7
453	Real-World Safety and Effectiveness of Denosumab in Patients with Osteoporosis: A Prospective, Observational Study in South Korea. <i>Endocrinology and Metabolism</i> , 2022, 37, 497-505.	3.0	9
454	Skeletal Aging. <i>Mayo Clinic Proceedings</i> , 2022, 97, 1194-1208.	3.0	29
455	Mass Screening for Low Bone Density Using Basic Check-Up Items. <i>IEEE Transactions on Computational Social Systems</i> , 2023, 10, 2579-2586.	4.4	2
457	Effect of Denosumab on the Change of Osteoclast Precursors Compared to Zoledronate Treatment in Postmenopausal Women with Osteoporosis. <i>Journal of Bone Metabolism</i> , 2022, 29, 93-101.	1.3	3
458	Cost-Effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in South Korea. <i>Journal of Bone Metabolism</i> , 2022, 29, 83-92.	1.3	1
459	Safety of denosumab versus zoledronic acid in the older adults with osteoporosis: a meta-analysis of cohort studies. <i>Archives of Osteoporosis</i> , 2022, 17, .	2.4	3
460	Advances in Our Understanding of the Mechanism of Action of Drugs (including Traditional Chinese) Tj ETQq1 1 0.784314 rgBT /Over	3.5	11
461	Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	40
462	A Randomized Controlled Dose-Escalation Study of LY06006, a Recombinant Humanized Monoclonal Antibody to RANKL, in Chinese Healthy Adults. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	2
463	The impact of sex steroids on osteonecrosis of the jaw. <i>Osteoporosis and Sarcopenia</i> , 2022, 8, 58-67.	1.9	4
465	Long-term compliance of patients with osteoporosis treatment and its effect to fracture occurrence. <i>Central European Journal of Public Health</i> , 2022, 30, S22-S26.	1.1	0
466	Biosimilar monoclonal antibodies in China: A patent review. <i>Bioengineered</i> , 2022, 13, 14503-14518.	3.2	3
467	Hungry bone syndrome like presentation following single-dose denosumab for hypercalcaemia secondary to sarcoidosis with IgA nephropathy. <i>BMJ Case Reports</i> , 2022, 15, e250647.	0.5	3
468	Bone remodeling: an operational process ensuring survival and bone mechanical competence. <i>Bone Research</i> , 2022, 10, .	11.4	85
469	Risk Factors for Denosumab Discontinuation in Patients with Postmenopausal Osteoporosis. <i>Modern Rheumatology</i> , 0, , .	1.8	2
470	Bone loss induced by cancer treatments in breast and prostate cancer patients. <i>Clinical and Translational Oncology</i> , 2022, 24, 2090-2106.	2.4	9
472	Rechallenge of denosumab in advanced giant cell tumor of the bone after atypical femur fracture: A case report and review of literature. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1

#	ARTICLE	IF	CITATIONS
473	Pros and Cons of Skeletal Medications in the COVID-19 Era. Current Treatment Options in Rheumatology, 2022, 8, 56-69.	1.4	3
474	Cancer Treatment-Induced Bone Loss: Role of Denosumab in Non-Metastatic Breast Cancer. Breast Cancer: Targets and Therapy, 0, Volume 14, 163-173.	1.8	4
475	Gaps and alternative surgical and non-surgical approaches in the bone fragility management: an updated review. Osteoporosis International, 2022, 33, 2467-2478.	3.1	9
476	Interventions for managing medication-related osteonecrosis of the jaw. The Cochrane Library, 2022, , 2022, .	2.8	19
477	What's New in Osteoporosis and Fragility Fractures. Journal of Bone and Joint Surgery - Series A, 2022, 104, 1509-1515.	3.0	4
478	A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk. Acta Pharmacologica Sinica, 2023, 44, 446-453.	6.1	3
479	Comparison of the efficacy between sequential therapy with teriparatide and denosumab and denosumab monotherapy in suppressing fragility fracture risk. Osteoporosis International, 2022, 33, 2409-2416.	3.1	3
480	Microgravity-Related Changes in Bone Density and Treatment Options: A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 8650.	4.1	9
482	Vertebral fractures after denosumab discontinuation for dental procedures: a consequence of distorted perceptions of risk. Medical Journal of Australia, 0, , .	1.7	1
483	Circulating Osteogenic Progenitor Cells Enhanced with Teriparatide or Denosumab Treatment. Journal of Clinical Medicine, 2022, 11, 4749.	2.4	1
484	Mortality Risk After Atypical Femoral Fracture: A Systematic Review and Meta-analysis. Endocrine Practice, 2022, 28, 1072-1077.	2.1	1
485	Polypharmacy in Osteoporosis Treatment. Clinics in Geriatric Medicine, 2022, 38, 715-726.	2.6	7
486	Comparable long-term retention rates and effects on bone mineral density of denosumab treatment in patients with osteoporosis with or without autoimmune inflammatory rheumatic diseases: real-life data. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2211245.	2.7	0
487	Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects. Expert Opinion on Investigational Drugs, 2022, 31, 1133-1142.	4.1	1
488	Incidence of Atypical Femoral Fractures in Patients on Osteoporosis Therapy—A Registry-Based Cohort Study. JBMR Plus, 2022, 6, .	2.7	5
489	Updated trabecular bone score accounting for the soft tissue thickness (TBSTT) demonstrated significantly improved bone microstructure with denosumab in the FREEDOM TBS post hoc analysis. Osteoporosis International, 2022, 33, 2517-2525.	3.1	4
490	Osteoporosis pathogenesis and treatment: existing and emerging avenues. Cellular and Molecular Biology Letters, 2022, 27, .	7.0	46
491	Evaluation of Clinical Outcomes by Therapeutic Dosing Interval of Denosumab (Prolia®) and Calcium-Vitamin D Prescriptions. Korean Journal of Clinical Pharmacy, 2022, 32, 185-190.	0.3	0

#	ARTICLE	IF	CITATIONS
492	Changes in dual energy X-ray absorptiometry parameters in postmenopausal women with osteoporosis who received at least 12 months of denosumab treatment. <i>Journal of Surgery and Medicine</i> , 2022, 6, 778-782.	0.1	0
493	Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 2112-2120.	2.8	27
494	Research on the Mechanism of Liuwei Dihuang Decoction for Osteoporosis Based on Systematic Biological Strategies. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-22.	1.2	2
495	Osteoporosis and Fragility Fractures: currently available pharmacological options and future directions. <i>Best Practice and Research in Clinical Rheumatology</i> , 2022, 36, 101780.	3.3	15
496	Bone health and cardiac transplantation. <i>Best Practice and Research in Clinical Rheumatology</i> , 2022, 36, 101770.	3.3	0
497	Yaşlı ve yetiştirkinlerde osteoporoz tedavisinde antirezorptif ajanların kararlaştırılması. <i>Cukurova Medical Journal</i> , 2022, 47, 1248-1255.	0.2	0
498	A bibliometric research based on hotspots and frontier trends of denosumab. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	1
499	UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naïve and castration-sensitive prostate cancer. <i>Canadian Urological Association Journal</i> , 2022, 16, .	0.6	0
500	Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation. <i>Current Osteoporosis Reports</i> , 2022, 20, 505-515.	3.6	11
502	Atypical femoral fracture in a bisphosphonate-naïve patient on denosumab for osteoporosis. <i>Archives of Osteoporosis</i> , 2022, 17, .	2.4	3
503	1,3-Dibenzyl-5-Fluorouracil Prevents Ovariectomy-Induced Bone Loss by Suppressing Osteoclast Differentiation. <i>Immune Network</i> , 2022, 22, .	3.6	0
504	What is the Risk of Developing Osteonecrosis Following Dental Extractions for Patients on Denosumab for Osteoporosis?. <i>Journal of Oral and Maxillofacial Surgery</i> , 2023, 81, 232-237.	1.2	2
505	Bone Health and Denosumab Discontinuation in Oncology Populations. <i>Oncologist</i> , 0, , .	3.7	0
506	Atypical Ulnar Fracture in an Older Woman with Osteoporosis with a Five-Year History of Denosumab Treatment: A Case Report. <i>Journal of hand surgery Asian-Pacific volume, The</i> , 2022, 27, 928-932.	0.4	1
507	The Dietary and Non-Dietary Management of Osteoporosis in Adult-Onset Celiac Disease: Current Status and Practical Guidance. <i>Nutrients</i> , 2022, 14, 4554.	4.1	4
509	Withdrawal of Denosumab in Patients with Primary Hyperparathyroidism: A Follow-up Report of the DENOCINA-Study. <i>Endocrine Practice</i> , 2022, , .	2.1	0
510	Management of fracture risk in CKD: traditional and novel approaches. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 456-472.	2.9	7
511	Where is bone science taking us?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2022, , 101791.	3.3	1

#	ARTICLE	IF	CITATIONS
512	The potential benefits of melatonin in the prevention and treatment of bone loss in response to microgravity. <i>Acta Astronautica</i> , 2023, 202, 48-57.	3.2	1
513	Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study. <i>Journal of Orthopaedic Translation</i> , 2023, 38, 117-125.	3.9	3
514	Receptor activator of nuclear factor- κ B ligand-mediated osteoclastogenesis signaling pathway and related therapeutic natural compounds. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	6
515	Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer. , 2022, 1, .		13
516	Denosumab Can Prevent Collapse in Patients with Early-Stage Steroid-Induced Osteonecrosis of the Femoral Head by Inhibiting Osteoclasts and Autophagy. <i>Orthopaedic Surgery</i> , 2023, 15, 256-265.	1.8	1
517	Long-term consequences of osteoporosis therapy with denosumab. <i>Archives of Endocrinology and Metabolism</i> , 2022, 66, 717-723.	0.6	0
518	The use of osteoclast inhibitors in metastatic breast cancer. <i>Romanian Journal of Orthopaedic Surgery and Traumatology</i> , 2022, 5, 28-34.	0.1	0
520	Is Adynamic Bone Always a Disease? Lessons from Patients with Chronic Kidney Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 7130.	2.4	3
521	Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies. <i>Cancers</i> , 2022, 14, 5727.	3.7	9
522	The Role of Bisphosphonates Prior to Denosumab Treatment on Rebound Fractures: A Mini Review. <i>Journal of Bone Metabolism</i> , 2022, 29, 217-223.	1.3	0
523	Denosumab Discontinuation. <i>Current Osteoporosis Reports</i> , 2023, 21, 95-103.	3.6	7
524	Moxibustion as adjuvant therapy for preventing bone loss in postmenopausal women: protocol for a randomised controlled trial. <i>BMJ Open</i> , 2022, 12, e062677.	1.9	1
525	Advancement in the Treatment of Osteoporosis and the Effects on Bone Healing. <i>Journal of Clinical Medicine</i> , 2022, 11, 7477.	2.4	7
526	Bone Turnover Markers: Basic Biology to Clinical Applications. <i>Endocrine Reviews</i> , 2023, 44, 417-473.	20.1	43
527	Murine Animal Models in Osteogenesis Imperfecta: The Quest for Improving the Quality of Life. <i>International Journal of Molecular Sciences</i> , 2023, 24, 184.	4.1	3
528	A Review on the Recent Trend in Osteoporosis Highly Cited Papers. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 0, , .	0.8	0
529	Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. <i>Annals of Internal Medicine</i> , 2023, 176, 182-195.	3.9	29
530	Pathogenesis and treatment of osteoporosis in patients with hemophilia. <i>Archives of Osteoporosis</i> , 2023, 18, .	2.4	3

#	ARTICLE	IF	CITATIONS
531	ADR3, a next generation i-body to human RANKL, inhibits osteoclast formation and bone resorption. <i>Journal of Biological Chemistry</i> , 2023, 299, 102889.	3.4	2
532	Closing the gap in osteoporosis management: the critical role of primary care in bone health. <i>Current Medical Research and Opinion</i> , 2023, 39, 387-398.	1.9	3
533	Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study. <i>Osteoporosis International</i> , 2023, 34, 573-584.	3.1	13
534	A summary of the Russian clinical guidelines on the diagnosis and treatment of osteoporosis. <i>Osteoporosis International</i> , 2023, 34, 429-447.	3.1	4
535	The potential benefits and mechanisms of protein nutritional intervention on bone health improvement. <i>Critical Reviews in Food Science and Nutrition</i> , 0, , 1-15.	10.3	4
536	Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis: a prospective study. <i>Aging Clinical and Experimental Research</i> , 2023, 35, 531-539.	2.9	1
537	Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone. <i>Nature Reviews Rheumatology</i> , 2023, 19, 307-317.	8.0	9
538	Risk of medication-related osteonecrosis of the jaw after dental extractions in patients receiving antiresorptive agents – A retrospective study of 240 patients. <i>Bone</i> , 2023, 170, 116722.	2.9	7
539	Myeloid Cells As a Promising Target for Brain – Bone Degenerative Diseases from a Metabolic Point of View. <i>Advanced Biology</i> , 2023, 7, .	2.5	0
541	Traitements s�quenciels de l'ost�oporo�se. , 2022, , 109-115.		0
542	Bone-targeted bioengineered bacterial extracellular vesicles delivering siRNA to ameliorate osteoporosis. <i>Composites Part B: Engineering</i> , 2023, 255, 110610.	12.0	18
544	Role of denosumab in bone erosions in rheumatoid arthritis. <i>Postgraduate Medical Journal</i> , 0, , .	1.8	0
545	Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness – adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension. <i>Osteoporosis International</i> , 2023, 34, 1075-1084.	3.1	3
546	Denosumab-induced hypocalcemia post bariatric surgery – a severe and protracted course: a case report. <i>Journal of Medical Case Reports</i> , 2023, 17, .	0.8	1
547	Comments on the use of Key Performance Indicators in evaluating the Organization of Fracture Liaison Services. <i>Osteoporosis and Bone Diseases</i> , 2023, 25, 28-42.	1.4	0
548	Wnt/ β -Catenin Promotes the Osteoblastic Potential of BMP9 Through Down-Regulating Cyp26b1 in Mesenchymal Stem Cells. <i>Tissue Engineering and Regenerative Medicine</i> , 2023, 20, 705-723.	3.7	1
549	Post hip fracture orthogeriatric care – a Canadian position paper addressing challenges in care and strategies to meet quality indicators. <i>Osteoporosis International</i> , 2023, 34, 1011-1035.	3.1	1
550	Multicenter study on atypical femoral fractures in patients with bone metastases taking bone-modifying agents. <i>Journal of Bone Oncology</i> , 2023, , 100478.	2.4	1

#	ARTICLE	IF	CITATIONS
552	Denosumab as a Pharmacological Countermeasure Against Osteopenia in Long Duration Spaceflight. <i>Aerospace Medicine and Human Performance</i> , 2023, 94, 389-395.	0.4	3
553	Advantages of zoledronic acid in the therapy of osteoporosis in real clinical practice. <i>Meditinskiy Sovet</i> , 2023, , 136-145.	0.5	0
554	Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis. <i>Rambam Maimonides Medical Journal</i> , 2023, 14, e0007.	1.0	4
555	Recommendations of the Spanish Society of Nephrology for the management of mineral and bone metabolism disorders in patients with chronic kidney disease: 2021 (SEN-MM). <i>Nefrologia</i> , 2023, , .	0.4	1
556	Special Considerations in Management of Atypical Femur Fractures. <i>Operative Techniques in Orthopaedics</i> , 2023, , 101039.	0.1	0
557	Denosumab treatment and infection risks in patients with osteoporosis: propensity score matching analysis of a national-wide population-based cohort study. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	0
558	Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60â€‰%mg dose: a prospective observational study. <i>Endocrine</i> , 2023, 80, 647-657.	2.3	0
559	Bone health and menopause: Osteoporosis prevention and treatment. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2023, , 101782.	4.7	3
560	Multiple Spontaneous Vertebral Fractures in a Younger Post-menopausal Woman Upon Stopping Denosumab Therapy. , 2023, 1, .		0
561	An overview of the management of osteoporosis in the aging female population. <i>Women's Health</i> , 2023, 19, 174550572311766.	1.5	2
562	Novel one-pot strategy for fabrication of a pH-Responsive bone-targeted drug self-frame delivery system for treatment of osteoporosis. <i>Materials Today Bio</i> , 2023, 20, 100688.	5.5	0
563	Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan. <i>Osteoporosis International</i> , 2023, 34, 1729-1737.	3.1	2
564	Engineering <i>Escherichia coli</i> Nissle 1917 as a microbial chassis for therapeutic and industrial applications. <i>Biotechnology Advances</i> , 2023, 67, 108202.	11.7	7
565	Atypical tibial fracture in breast cancer patient with bone metastasis receiving denosumab therapy: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2023, 17, .	0.8	1
566	Denosumab use in osteogenesis imperfecta: an update on therapeutic approaches. <i>Annals of Pediatric Endocrinology and Metabolism</i> , 2023, 28, 98-106.	2.3	3
567	Refraction risk and all-cause mortality after vertebral fragility fractures: Anti-osteoporotic medications matter. <i>Journal of the Formosan Medical Association</i> , 2023, 122, S65-S73.	1.7	6
568	Denosumab for giant cell tumors of bone from 2010 to 2022: a bibliometric analysis. <i>Clinical and Experimental Medicine</i> , 0, , .	3.6	0
569	Denosumab for osteoporosis in patients with primary hyperparathyroidism and mild-to-moderate renal insufficiency. <i>Endocrine</i> , 2023, 81, 368-378.	2.3	0

#	ARTICLE	IF	CITATIONS
570	MicroRNAs in Bone Formation and Homeostasis. , 2023, , 369-394.		0
571	The comparable efficacy of denosumab on bone mineral density in rheumatoid arthritis patients with postmenopausal osteoporosis: A retrospective case-control study. <i>Medicine (United States)</i> , 2023, 102, e34219.	1.0	0
572	A nomogram prediction model for refracture in elderly patients with osteoporotic vertebral compression fractures after percutaneous vertebroplasty. <i>European Spine Journal</i> , 2023, 32, 3919-3926.	2.2	1
573	Atypical femoral fracture in a multiple myeloma patient undergoing treatment with denosumab: A case report and literature review. <i>International Journal of Surgery Case Reports</i> , 2023, 108, 108456.	0.6	1
574	Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system. <i>Scientific Reports</i> , 2023, 13, .	3.3	3
575	Impact of the COVID-19 Pandemic on Adherence to Denosumab Therapy: A Single Center Study. <i>Asian Spine Journal</i> , 0, , .	2.0	1
577	Sulforaphene suppresses RANKL-induced osteoclastogenesis and LPS-induced bone erosion by activating Nrf2 signaling pathway. <i>Free Radical Biology and Medicine</i> , 2023, 207, 48-62.	2.9	1
578	Long-term and sequential treatment for osteoporosis. <i>Nature Reviews Endocrinology</i> , 2023, 19, 520-533.	9.6	13
579	Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	3
580	Argentine Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Postmenopausal Women and Men Aged 50 Years and Older. <i>Journal of Clinical Rheumatology</i> , 2023, 29, e59-e70.	0.9	4
581	Trabecular bone deterioration in a postmenopausal female suffering multiple spontaneous vertebral fractures due to a delayed denosumab injection – A post-treatment re-initiation bone biopsy-based case study. <i>Bone Reports</i> , 2023, 19, 101703.	0.4	1
582	Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study. <i>Osteoporosis International</i> , 2023, 34, 1961-1973.	3.1	1
583	Combined and sequential therapies with anabolic and antiresorptive drugs in the management. , 2023, 3, 7-15.		0
584	Alzheimer’s disease and its associated risk of bone fractures: a narrative review. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	1
585	Sequential Therapy for the Long-Term Treatment of Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2024, 109, 303-311.	3.6	4
587	Atypical Femoral Fracture in Hypophosphatasia: A Systematic Review. <i>International Journal of Endocrinology</i> , 2023, 2023, 1-9.	1.5	0
588	Osteoporosis: Spotlight on current approaches to pharmacological treatment. <i>Turkish Journal of Physical Medicine and Rehabilitation</i> , 2023, 69, 140-152.	0.9	3
589	Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab. <i>Journal of Clinical Medicine</i> , 2023, 12, 5874.	2.4	0

#	ARTICLE	IF	CITATIONS
590	Idiopathic avascular maxillary necrosis: A case report. <i>Oral and Maxillofacial Surgery Cases</i> , 2023, 9, 100332.	0.4	0
591	Romozosumab in osteoporosis: yesterday, today and tomorrow. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	3
592	Treatment Persistence and Medication Switch Associated With Subsequent Fractures After Osteoporotic Fractures. <i>Journal of Clinical Endocrinology and Metabolism</i> , 0, , .	3.6	0
593	Research Progress on the Application of Deshuzumab in Osteoporosis. <i>Advances in Clinical Medicine</i> , 2023, 13, 13454-13463.	0.0	0
594	Denosumab: Clinical Applications, Outcomes, and Perspectives in Osteoporosis. , 2023, , 21-34.		0
595	Prevalence of denosumab-induced hypocalcemia: a retrospective observational study of patients routinely monitored with ionized calcium post-injection. <i>Osteoporosis International</i> , 2024, 35, 173-180.	3.1	1
596	Improvement of proportion of days covered for denosumab under implementation of clinical pharmacist adherence management system: normal and COVID-19 period. <i>Osteoporosis International</i> , 0, , .	3.1	0
597	The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial. <i>Osteoporosis International</i> , 2024, 35, 255-263.	3.1	2
600	Molecular and Cellular Mechanisms of Osteoporosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 15772.	4.1	2
601	Drug-Related Bone and Soft Tissue Disorders. , 2023, , 1-23.		0
602	Follow-up Bone Mineral Density Testing: 2023 Official Positions of the International Society for Clinical Densitometry. <i>Journal of Clinical Densitometry</i> , 2024, 27, 101440.	1.2	1
603	Drug Therapeutics of Osteoporosis, Vertebral Fracture and Nonunion. , 0, , .		0
604	Risk factors associated with prognosis of patients with medication-related osteonecrosis of the jaw. <i>Head and Neck</i> , 2024, 46, 282-290.	2.0	0
605	Postmenopausal Osteoporosis. <i>New England Journal of Medicine</i> , 2023, 389, 1979-1991.	27.0	8
607	Osteoclasts at Bone Remodeling: Order from Order. <i>Results and Problems in Cell Differentiation</i> , 2024, , 227-256.	0.7	1
608	Position Statement: Postmenopausal Osteoporosis Treatment Strategies in Korea. <i>Journal of Bone Metabolism</i> , 2023, 30, 289-295.	1.3	0
609	Adherence of denosumab treatment for low bone mineral density in Japanese people living with HIV: a retrospective observational study. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2023, 9, .	1.0	0
610	Navigating the complexities and controversies of medication-related osteonecrosis of the jaw (MRONJ): a critical update and consensus statement. <i>Acta Chirurgica Belgica</i> , 2024, 124, 1-11.	0.4	0

#	ARTICLE	IF	CITATIONS
611	New Horizons- Translational Aspect of Osteomorphs. Journal of Clinical Endocrinology and Metabolism, 0, , .	3.6	0
612	Using sequential pharmacotherapy for the treatment of osteoporosis: an update of the literature. Expert Opinion on Pharmacotherapy, 2023, 24, 2175-2186.	1.8	0
613	Efficacy of denosumab in the treatment of hypercalcemic renal dysfunction in sarcoidosis: a case report. Osteoporosis International, 0, , .	3.1	0
614	Cistanche deserticola improves ovariectomized-induced osteoporosis mainly by regulating lipid metabolism: Insights from serum metabolomics using UPLC/Q-TOF-MS. Journal of Ethnopharmacology, 2024, 322, 117570.	4.1	2
615	Effect of denosumab on glucose metabolism in postmenopausal osteoporotic women with prediabetes: a study protocol for a 12-month multicenter, open-label, randomized controlled trial. Trials, 2023, 24, .	1.6	0
616	Breaking Osteoclastâ€Acid Vicious Cycle to Rescue Osteoporosis via an Acid Responsive Organic Frameworkâ€Based Neutralizing and Gene Editing Platform. Small, 0, , .	10.0	0
617	Correction: Efficacy of Denosumab in the Treatment of Postmenopausal Osteoporosis: One-year Follow-up, Single Center Study. Turk Osteoporoz Dergisi, 2023, 29, 184-185.	0.3	0
618	Emerging Landscape of Osteogenesis Imperfecta Pathogenesis and Therapeutic Approaches. ACS Pharmacology and Translational Science, 2024, 7, 72-96.	4.9	1
619	Chitosan/Nanohydroxyapatite/Hydroxyethyl-cellulose-based printable formulations for local alendronate drug delivery in osteoporosis treatment. Carbohydrate Polymer Technologies and Applications, 2024, 7, 100418.	2.6	0
620	Cardiometabolic Effects of Denosumab in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression: RCT. Journal of Clinical Endocrinology and Metabolism, 0, , .	3.6	0
621	Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfectaâ€”the First Prospective Comparative Study. Journal of Clinical Endocrinology and Metabolism, 0, , .	3.6	0
622	Cost-consequence analysis of continuous denosumab therapy for osteoporosis treatment in South Korea. BMC Musculoskeletal Disorders, 2024, 25, .	1.9	0
623	Effect of Hyperprolactinemia on Bone Metabolism: Focusing on Osteopenia/Osteoporosis. International Journal of Molecular Sciences, 2024, 25, 1474.	4.1	0
624	Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study. Journal of Bone and Mineral Research, 2024, 39, 202-210.	2.8	0
625	Basic-helix-loop-helix family member e41 suppresses osteoclastogenesis and abnormal bone resorption disease via NFATc1. IScience, 2024, 27, 109059.	4.1	0
626	Association of chronic liver disease with bone diseases and muscle weakness. Journal of Bone and Mineral Metabolism, 0, , .	2.7	0
627	Treatment Sequence for Osteoporosis. Endocrine Practice, 2024, 30, 490-496.	2.1	0
628	Inhibitory effects of norcantharidin on titanium particle-induced osteolysis, osteoclast activation and bone resorption via MAPK pathways. International Immunopharmacology, 2024, 129, 111655.	3.8	0

#	ARTICLE	IF	CITATIONS
629	Antiresorptive Drugsâ€™™ Role in Management of Postmenopausal Osteoporosis. Endocrinology, 2024, , 1-20.	0.1	0
630	Osteoporosis management-current and future perspectives â€™“ A systemic review. Journal of Orthopaedics, 2024, 53, 101-113.	1.3	0
631	Anti-osteoporotic treatments in the era of non-alcoholic fatty liver disease: friend or foe. Frontiers in Endocrinology, 0, 15, .	3.5	0
632	The 2024 Guidelines for Osteoporosis - Korean Society of Menopause. Journal of Menopausal Medicine, 2024, 30, 1.	1.1	0
633	Analysis of SIRT1 Gene SNPs and Clinical Characteristics in Medication-Related Osteonecrosis of the Jaw. International Journal of Molecular Sciences, 2024, 25, 3646.	4.1	0
634	Causal Relationship of Obstructive Sleep Apnea with Bone Mineral Density and the Role of BMI. Nature and Science of Sleep, 0, Volume 16, 325-333.	2.7	0
635	è†ˆâ°Šâ€»ã•ã,%œè <ãŸç” ðæŸâ€»â- ã®â°†æŸâ±•æœ. Journal of UOEH, 2024, 46, 79-86.	0.6	0